

Public Use Data Sets

Documentation – Publications as of December 2016

1. ACCORD Study Group, Gerstein HC, Miller ME, Genuth S, Ismail-Beigi F, Buse JB, Goff DC Jr, Probstfield JL, Cushman WC, Ginsberg HN, Bigger JT, Grimm RH Jr, Byington RP, Rosenberg YD, Friedewald WT. Long-Term Effects of Intensive Glucose Lowering on Cardiovascular Outcomes. *N Engl J Med* 2011;364:818-28. PMID: 21366473 PMCID: PMC4083508.
2. ACCORD Study Group, ACCORD Eye Study Group, Chew EY, Ambrosius WT, Davis MD, Danis RP, Gangaputra S, Greven CM, Hubbard L, Esser BA, Lovato JF, Perdue LH, Goff DC Jr, Cushman WC, Ginsberg HN, Elam MB, Genuth S, Gerstein HC, Schubart U, Fine LJ. Effects of Medical Therapies on Retinopathy Progression in Type 2 Diabetes. *N Engl J Med* 2010;363:233-44. PMID: 20587587 PMCID: PMC4026164.
3. ACCORD Study Group, Cushman WC, Evans GW, Byington RP, Goff DC Jr, Grimm RH Jr, Cutler JA, Simons-Morton DG, Basile JN, Corson MA, Probstfield JL, Katz L, Peterson KA, Friedewald WT, Buse JB, Bigger JT, Gerstein HC, Ismail-Beigi F. Effects of Intensive Blood-Pressure Control in Type 2 Diabetes Mellitus. *N Engl J Med* 2010;362:1575-85. PMID: 20228401 PMCID: PMC4123215.
4. ACCORD Study Group, Ginsberg HN, Elam MB, Lovato LC, Crouse JR 3rd, Leiter LA, Linz P, Friedewald WT, Buse JB, Gerstein HC, Probstfield J, Grimm RH, Ismail-Beigi F, Bigger JT, Goff DC Jr, Cushman WC, Simons-Morton DG, Byington RP. Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus. *N Engl J Med* 2010;362:1563-74. PMID: 20228404 PMCID: PMC2879499.
5. ACCORD Study Group, Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH Jr, Probstfield JL, Simons-Morton DG, Friedewald WT. Effects of intensive glucose lowering in type 2 diabetes. *N Engl J Med* 2008;358:2545-59. PMID: 18539917 PMCID: PMC4551392
6. ACCORD Study Group, Buse JB, Bigger JT, Byington RP, Cooper LS, Cushman WC, Friedewald WT, Genuth S, Gerstein HC, Ginsberg HN, Goff DC Jr, Grimm RH Jr, Margolis KL, Probstfield JL, Simons-Morton DG, Sullivan MD. Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. *Am J Cardiol* 2007;99(suppl):21i–33i. PMID: 17599422.
7. ACCORD Study Group, Bastien A. The ACCORD trial: A multidisciplinary approach to control cardiovascular risk in Type 2 diabetes mellitus. *Practical Diabet* 2004;23:1-7. (No PMID).
8. ACCORD Study Group, Gerstein HC, Beavers DP, Bertoni AG, Bigger JT, Buse JB, Craven TE, Cushman WC, Giddings SJ, Seaquist ER, Grimm RH, Fonseca V, Geller NL, Genuth S, Hramiak I, Ismail-Beigi F, Kirby R, Lopez-Jimenez CR, Probstfield J, Riddle MC, Friedewald WT. 9-year Effects of 3.7 Years of Intensive Glycemia Control on Cardiovascular Outcomes. *Diabetes Care* 2016;39:701-8. PMID: 26822326 PMCID: PMC4839177.
9. ACCORDION Eye Study Group and ACCORDION Study Group, Chew EY, Lovato JF, Davis MD, Gerstein HC, Danis RP, Ismail-Beigi F, Genuth S, Greven CM, Perdue LH, Cushman WC, Elam MB, Bigger JT, Ginsberg HN, Goff DC, Ambrosius WT. Persistent Effects of Intensive Glycemic Control on Retinopathy in Type 2 Diabetes in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Follow-On Study. *Diabetes Care* 2016;39:1089-100. PMID: 27289122 PMCID: PMC4915557.
10. Ali MK, Feeney P, Hire D, Simmons DL, O'Connor PJ, Ganz-Lord F, Goff D Jr, Zhang P, Andersen R, V Narayan KM, Sullivan MD. Glycaemia and correlates of patient-reported outcomes in ACCORD trial participants. *Diabet Med* 2012;29:e67-e74. PMID: 22141437.

11. Ambrosius WT, Danis RP, Goff DC Jr, Greven CM, Gerstein HC, Cohen RM, Riddle MC, Miller ME, Buse JB, Bonds DE, Peterson KA, Rosenberg YD, Perdue LH, Esser BA, Seaquist LA, Felicetta JV, Chew EY; ACCORD Study Group. Lack of association between thiazolidinediones and macular edema in type 2 diabetes: the ACCORD eye substudy. *Arch Ophthalmol* 2010;128:312-8. PMID: 20212201 PMCID: PMC3010554.
12. Anderson RT, Narayan KM, Feeney P, Goff D Jr, Ali MK, Simmons DL, Sperl-Hillen JA, Bigger T, Cuddihy R, O'Conner PJ, Sood A, Zhang P, Sullivan MD; Action to Control Cardiovascular Risk in Diabetes (ACCORD) Investigators. Effect of intensive glycemic lowering on health-related quality of life in type 2 diabetes: ACCORD trial. *Diabetes Care* 2011;34:807-12. PMID: 21346183 PMCID: PMC3064032.
13. Barzilay JI, Howard AG, Evans GW, Fleg JL, Cohen RM, Booth GL, Kimel AR, Pedley CF, Cushman WC. Intensive Blood Pressure Treatment Does Not Improve Cardiovascular Outcomes in Centrally Obese Hypertensive Individuals With Diabetes: The Action to Control Cardiovascular Risk in Diabetes (ACCORD) Blood Pressure Trial. *Diabetes Care* 2012;35:1401-5. PMID: 22723577 PMCID: PMC3379577.
14. Barzilay JI, Lovato JF, Murray AM, Williamson J, Ismail-Beigi F, Karl D, Papademetriou V, Launer LJ. Albuminuria and Cognitive Decline in People with Diabetes and Normal Renal Function. *Clin J Am Soc Nephrol* 2013;8:1907-14. PMID 23990163 PMCID: PMC3817915.
15. Barzilay JI, Morgan TM, Murray AM, Bryan RN, Williamson JD, Schnall A, Launer LJ. Brain MRI Volume Findings in Diabetic Adults With Albuminuria: The ACCORD-MIND Study. *J Gerontol A Biol Sci Med Sci* 2016;71:803-10. PMID: 26589241 PMCID: PMC4888390.
16. Berard L, Cameron B, Woo V, Stewart J. Replacing Insulin Glargine with Neutral Protamine Hagedorn (NPH) Insulin in a Subpopulation of Study Subjects in the Action to Control Cardiovascular Risk in Diabetes (ACCORD): Effects on Blood Glucose Levels, Hypoglycemia and Patient Satisfaction. *Can J Diabetes* 2015;39:296-301. PMID: 25819531.
17. Bonds DE, Craven TE, Buse J, Crouse JR, Cuddihy R, Elam M, Ginsberg HN, Kirchner K, Marcovina S, Mychaleckyj JC, O'Connor PJ, Sperl-Hillen JA. Fenofibrate-associated changes in renal function and relationship to clinical outcomes among individuals with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) experience. *Diabetologia* 2012;55:1641-50. PMID: 22450889 PMCID: PMC3374398.
18. Bonds DE, Kurashige EM, Bergenstal R, Brillon D, Domanski M, Felicetta JV, Fonseca VA, Hall K, Hramiak I, Miller ME, Osei K, Simons-Morton DG, for the ACCORD Study Group. Severe hypoglycemia monitoring and risk management procedures in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. *Am J Cardiol* 2007;99(suppl):80i- 89i. PMID: 17599428.
19. Bonds DE, Miller ME, Bergenstal RM, Buse JB, Byington RP, Cutler JA, Dudl RJ, Ismail-Beigi F, Kimel AR, Hoogwerf B, Horowitz KR, Savage PJ, Seaquist ER, Simmons DL, Sivitz WI, Speril-Hillen JM, Sweeney ME. The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. *BMJ* 2010;340:b4909. PMID: 20061358 PMCID: PMC2803744.
20. Bonds DE, Miller ME, Dudl J, Feinglos M, Ismail-Beigi F, Malozowski S, Seaquest E, Simmons DL, Sood A. Severe hypoglycemia symptoms, antecedent behaviors, immediate consequences and association with glycemia medication usage: secondary analysis of the ACCORD clinical trial data. *BMC Endocr Disord* 2012 May 30;12:5. doi: 10.1186/1472-6823-12-5. PMID: 22646230 PMCID: PMC3433360.

21. Bryan RN, Bilello M, Davatzikos C, Lazar RM, Murray A, Horowitz K, Lovato J, Miller ME, Williamson J, Launer LJ. Effect of Diabetes on Brain Structure: The Action to Control Cardiovascular Risk in Diabetes MR Imaging Baseline Data. *Radiology*. 2014;272:210-6. doi: 10.1148/radiol.14131494. Epub 2014 Apr 29. PMID:24779562 PMCID: PMC4263658.
22. Buse JB. Glycemic Targets in Diabetes Care: Emerging Clarity after ACCORD. *Trans Am Clin Climatol Assoc*. 2015;126:62-76. PMID: 26330660 PMCID: PMC4530694.
23. Calles-Escandón J, Lovato LC, Simons-Morton DG, Kendall DM, Pop-Busui R, Cohen RM, Bonds DE, Fonseca VA, Ismail-Beigi F, Banerji MA, Failor A, Hamilton B. Effect of intensive compared with standard glycemia treatment strategies on mortality by baseline subgroup characteristics: The ACCORD trial. *Diabetes Care* 2010;33:721-7. PMID: 20103550 PMCID: PMC2845012.
24. Casanova R, Saldana S, Chew EY, Danis RP, Greven CM, Ambrosius WT. Application of Random Forests Methods to Diabetic Retinopathy Classification Analyses. *PLoS One* 2014;18:9(6): e98587. PMID: 24949623 PMCID: PMC4062420.
25. Chen LY, Bigger JT, Hickey KT, Chen H, Lopez-Jimenez C, Banerji MA, Evans G, Fleg JL, Papademetriou V, Thomas AT, Woo V, Seaquist ER, Soliman EZ. Effect of Intensive Blood Pressure-Lowering on Incident Atrial Fibrillation and P-Wave Indices in the ACCORD Blood Pressure Trial. *Am J Hypertension* 2016;29:1276-82. PMID: 26476086 PMCID: PMC5055733.
26. Chew EY, Ambrosius WT, Howard LT, Greven CM, Johnson S, Danis RP, Davis MD, Genuth S, Domanski M, for the ACCORD Study Group. Rationale, Design, and Methods of the Action to Control Cardiovascular Risk in Diabetes Eye Study (ACCORD-EYE). *Am J Cardiol* 2007;99(suppl):103i-111i. PMID: 17599420.
27. Chew E, Davis MD, Danis RP, Lovato JF, Perdue LH, Greven C, Genuth S, Goff DC, Leiter LA, Ismail-Beigi F, Ambrosius WT. The Effects of Medical Management on the Progression of Diabetic Retinopathy in Persons with Type 2 Diabetes: The ACCORD Eye Study. *Ophthalmology* 2014;121:2443-51. PMID: 25172198 PMCID: PMC4252767.
28. Chow LS, Chen H, Miller ME, Marcovina SM, Seaquist ER. Biomarkers Related to Severe Hypoglycaemia and Lack of Good Control in ACCORD. *Diabetologia* 2015;58:1160-6. PMID: 25652389 PMCID: PMC4416999.
29. Chow LS, Chen H, Miller ME, Marcovina SM, Seaquist ER. Biomarkers associated with severe hypoglycaemia and death in ACCORD. *Diabet Med* 2016; 33:1076-83. PubMed PMID: 26261902 PMCID: PMC4751070.
30. CONTROL Group, Turnbull FM, Abraira C, Anderson RJ, Byington RP, Chalmers JP, Duckworth WC, Evans GW, Gerstein HC, Holman RR, Moritz TE, Neal BC, Ninomiya T, Patel AA, Paul SK, Travert F, & M. Woodward M. Intensive Glucose Control and Macrovascular Outcomes in Type 2 Diabetes. *Diabetologia* 2009;52:2288–98. PMID: 19655124.
31. Cukierman-Yaffe T, Gerstein HC, Williamson JD, Lazar RM, Lovato L, Miller ME, Coker LH, Murray A, Sullivan MD, Marcovina SM, Launer LJ, for the ACCORD Memory in Diabetes (MIND) Investigators. Relationship Between Baseline Glycemic Control and Cognitive Function in Individuals With Type 2 Diabetes and Other Cardiovascular Risk Factors: the Action to Control Cardiovascular Risk in Diabetes-Memory in Diabetes (ACCORD-MIND) Trial. *Diabetes Care* 2009;32:221-6. PMID: 19171735 PMCID: PMC2628683.

32. Cushman WC, Grimm RH, Cutler JA, Evans GW, Capes S, Corson MA, Sadler LS, Alderman MH, Peterson K, Bertoni A, Basile JN, for the ACCORD Study Group. Rationale and design for the blood pressure intervention of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. *Am J Cardiol* 2007;99(suppl):44i–55i. PMID: 17599425.
33. Drake TC, Hsu FC, Hire D, Chen SH, Cohen RM, McDuffie R, Nysten E, O'Connor, Rehman S, Seaquist ER. Factors Associated With Failure to Achieve a Glycated Haemoglobin Target of <8% in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial. *Diabetes Obes Metab* 2016;18:92-5. PMID: 26435375.
34. Elam M, Lovato LC, Ginsberg H. Role of Fibrates in Cardiovascular Disease Prevention, the ACCORD-Lipid Perspective. *Curr Opin Lipidol* 2011;22:55-61. PMID: 21102326.
35. Elam M, Lovato L, Ginsberg H. The ACCORD-Lipid Study: Implications for Treatment of Dyslipidemia in Type 2 Diabetes Mellitus. *Clin Lipidol*. 2011;6:9-20. PMID: 26207146 PMCID: PMC4509601.
36. Elam MB, Ginsberg HN, Lovato LC, Corson M, Largay J, Leiter LA, Lopez C, O'Connor PJ, Sweeney ME, Weiss D, Friedewald WT, Buse JB, Gerstein HC, Probstfield J, Grimm R, Ismail-Beigi F, Goff DC, Fleg JL, Rosenberg Y, Byington RP, for the ACCORDION Study Investigators. Effect of fenofibrate therapy on long-term cardiovascular risk in statin-treated patients with type II diabetes. *JAMA Cardiol* 2017;2:1-11. (To be published online Dec 28, 2016 ahead of print.)
37. Erus G, Battapady H, Lovato J, Miller ME, Williamson JD, Launer LJ, Bryan RN, Davatzikos C. Spatial Patterns of Structural Brain Changes in Type-2 Diabetic Patients and Their Longitudinal Progression with Intensive Control of Blood Glucose. *Diabetes Care* 2015;38:97-104. PMID: 25336747 PMCID: PMC4274773.
38. Espeland MA, Probstfield J, Hire D, Redmon JB, Evans GW, Coday M, Lewis CE, Johnson KC, Wilmoth S, Bahnson J, Dulin MF, Green JB, Knowler WC, Kitabchi A, Murillo AL, Osei K, Rehman SU, Cushman WC, the Look AHEAD Research Group, and the ACCORD Study Group. Systolic Blood Pressure Control Among Individuals With Type 2 Diabetes: A Comparative Effectiveness Analysis of Three Interventions. *Am J Hypertension* 2015;28:995-1009. PMID: 25666468 PMCID: PMC4506323.
39. Fatemi O, Yuridistky E, Tsioufis C, Tsachris D, Morgan T, Basile J, Bigger T, Cushman W, Goff D, Soliman E, Thomas A, Papademetriou V. Impact of Intensive Glycemic Control on the Incidence of Atrial Fibrillation and Associated Cardiovascular Outcomes on Patients with Type 2 Diabetes Mellitus (from the Action to Control Cardiovascular Risk in Diabetes Study). *Am J Cardiology* 2014;114:1217-22. PMID: 25159234 PMCID: PMC4291278.
40. Fleg JL, Evans GW, Margolis KL, Barzilay J, Basile JN, Bigger JT, Cutler JA, Grimm R, Pedley C, Peterson K, Pop-Busui R, Sperl-Hillen J, Cushman WC. Orthostatic Hypotension in the ACCORD (Action to Control Cardiovascular Risk in Diabetes) Blood Pressure Trial: Prevalence, Incidence, and Prognostic Significance. *Hypertension* 2016;68:888-95. PMID: 27504006 PMCID: PMC5016241.
41. Fonseca V, McDuffie R, Calles J, Cohen RM, Feeney P, Feinglos M, Gerstein HC, Ismail-Beigi F, Morgan TM, Pop-Busui R, Riddle MC; ACCORD Study Group. Determinants of weight gain in the action to cardiovascular risk in diabetes trial. *Diabetes Care* 2013;36:2162-8. PMID: 23412077 PMCID: PMC3714487.
42. Gangaputra S, Lovato J, Hubbard L, Davis MD, Esser BA, Ambrosius W, Chew EY, Greven C, Perdue LH, Wong WT, Condren A, Wilkinson CP, Agrón E, Adler S and Danis RP, for the ACCORD Eye Research Group. Comparison of Standardized Clinical Classification with Fundus Photograph Grading for the assessment of Diabetic Retinopathy and Diabetic Macular Edema Severity. *Retina* 2013;33:1393-9. PMID: 23615341 PMCID: PMC3706017.

43. Genuth S, Ismail-Beigi F. Clinical Implications of the ACCORD Trial. *J Clin Endocrinol Metab.* 2012;97:41-8. PMID: 22049171.
44. Gerstein HC, Ambrosius WT, Danis R, Ismail-Beigi F, Cushman W, Calles J, Banerji MA, Schubart U, Chew EY. Diabetic Retinopathy, its Progression and Incident Cardiovascular Events in the ACCORD trial. *Diabetes Care* 2013;36:1266-71. PMID: 23238658 PMCID: PMC3631868.
45. Gerstein HC, Riddle MC, Kendall DM, Cohen RM, Golland R, Feinglos MN, Kirk JK, Hamilton BP, Ismail-Beigi F, Feeney P. for the ACCORD Study Group. Glycemia treatment strategies in the ACCORD trial. *Am J Cardiol* 2007;99(suppl):34i-43i. PMID: 17599423.
46. Gerstein HC, Miller ME, Ismail-Beigi F, Largay J, McDonald C, Lochnan HA, Booth GL. For the ACCORD Study Group. Effect of Intensive Glycemic Control on Ischemic Heart Disease: Analysis of Data from the Randomised, Controlled ACCORD Trial. *Lancet* 2014;384:1936-41. PMID: 25988437 PMCID: PMC4397008.
47. Getaneh A, Light LS, Brillon DJ, Calles Escandón J, Felicetta J, Evans GW, Lopez-Jimenez CR, Cuddihy R, Bigger JT. Diabetes Control Among Hispanics in the Action to Control Cardiovascular Risk in Diabetes Trial. *J Gen Intern Med* 2012;27:1499-505. PMID: 22744725 PMCID: PMC3475813.
48. Ginsberg HN, Bonds DE, Lovato LC, Crouse JR, Elam MB, Linz PE, O'Connor PJ, Leiter LA, Weiss D, Lipkin E, Fleg JL, for the ACCORD Study Group. Evolution of the lipid trial protocol of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. *Am J Cardiol* 2007;99(suppl):56i-67i. PMID: 17599426.
49. Ginsberg HN. The ACCORD (Action to Control Cardiovascular Risk in Diabetes) Lipid Trial: What We Learn From Subgroup Analyses. *Diabetes Care* 2011;34(suppl):S107-8. PMID: 21525439 PMCID:PMC3632145.
50. Graham HT, Rotroff DM, Marvel SW, Buse JB, Havener TM, Wilson AG, Wagner MJ, Motsinger-Reif AA: ACCORD/ACCORDion Investigators. Incorporating Concomitant Medications into Genome-Wide Analyses for the Study of Complex Disease and Drug Response. *Front Genet* 2016;17:138. eCollection 2016. PMID: 27775101 PMCID: PMC5013254.
51. Goff DC, Gerstein HC, Ginsberg HN, Cushman WC, Margolis KL, Byington RP, Buse JB, Genuth S, Probstfield JL, Simons-Morton DG, for the ACCORD Study Group. Prevention of cardiovascular disease in persons with type 2 diabetes mellitus: current knowledge and rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. *Am J Cardiol* 2007;99(suppl):4i-20i. PMID: 17599424.
52. Hempe JM, Lui S, Myers L, McCarter RJ, Buse JB, Fonseca V. The Hemoglobin Glycation Index Identifies Subpopulations With Harms or Benefits From Intensive Treatment in the ACCORD Trial. *Diabetes Care* 2015;38:1067-74. PMID: 25887355 PMCID: PMC4439529.
53. Herskovits EH, Bryan RN, Yang F. Automated Bayesian segmentation of microvascular white-matter lesions in the ACCORD-MIND study. *Adv Med Sci* 2008;53:182-90. PMID: 18842559.
54. Hugenschmidt CE, Lovato JF, Ambrosius WT, Bryan RN, Gerstein HC, Horowitz KR, Launer LJ, Lazar RM, Murray AM, Chew EY, Danis RP, Williamson JD, Miller ME, Ding J. The Cross-sectional and Longitudinal Associations of Diabetic Retinopathy With Cognitive Function and Brain MRI Findings: The Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial. *Diabetes Care* 2014;37:3244-52. PMID: 25193529 PMCID: PMC4237980.
55. Isakova T, Craven T, Lee J, Scialla J, Xie H, Wahl P, Marcovina S, Byington RP, Wolf M. Fibroblast Growth Factor 23 and Incident Chronic Kidney Disease in Type 2 Diabetes. *Clin J Am Soc Nephrol* 2015;10:28-38. PMID: 25343949 PMCID: PMC4284418.
56. Isakova T, Craven TE, Scialla JJ, Nickolas TL, Scnall A, Barzilaey J, Schwartz AV. Change in Estimated Glomerular Filtration Rate and Fracture Risk in the Action to Control Cardiovascular Risk in Diabetes Trial. *Bone* 2015;78:23-7. PMID: 25937184 PMCID: PMC4466209.

57. Ismail-Beigi F, Craven T, Banerji MA, Basile J, Calles J, Cohen RM, Cuddihy R, Cushman WC, Genuth S, Grimm RH Jr, Hamilton BP, Hoogwerf B, Karl D, Katz L, Krikorian A, O'Connor P, Pop-Busui R, Schubart U, Simmons D, Taylor H, Thomas A, Weiss D, Hramiak I; ACCORD trial group. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. *Lancet* 2010;376:419-30. PMID: 20594588 PMCID: PMC4123233.
58. Ismail-Beigi F, Craven TE, O'Connor PJ, Karl D, Calles-Escandon J, Hramiak I, Genuth S, Cushman WC, Gerstein HC, Probstfield JL, Katz L, Schubart U. Combined intensive blood pressure and glycemic control does not produce an additive benefit on microvascular outcomes in type 2 diabetic patients. *Kidney Int* 2012;81:586-94. PMID: 22166848 PMCID: PMC4641306.
59. Kingry C, Bastien A, Booth G, Geraci TS, Kirpach BR, Lovato LC, Margolis KL, Rosenberg Y, Sperl-Hillen JM, Vargo L, Williamson JD, Probstfield JL, for the ACCORD Study Group. Recruitment strategies in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial. *Am J Cardiol* 2007;99(suppl):68i-79i. PMID: 17599427.
60. Kirk JK, Craven T, Lipkin EW, Katula J, Pedley C, O'Connor PJ, Margolis KL. Longitudinal changes in dietary fat intake and associated changes in cardiovascular risk factors in adults with type 2 diabetes: the ACCORD Trial. *Diabetes Res Clin Pract* 2013;100:61-8. PMID: 23490598 PMCID: PMC4158818.
61. Lao Z, Shen D, Liu D, Jawad AF, Melhem ER, Launer LJ, Bryan RN, Davatzikos C. Computer-assisted segmentation of white matter lesions in 3D MR images using support vector machine. *Acad Radiol* 2008;15:300-13. PMID: 18280928 PMCID: PMC2528894.
62. Launer LJ, Miller ME, Williamson JD, Lazar RM, Gerstein HC, Murray AM, Sullivan M, Horowitz KR, Ding J, Marcovina S, Lovato LC, Lovato J, Margolis KL, O'Connor P, Lipkin EW, Hirsch J, Coker L, Maldjian J, Sunshine JL, Truwit C, Davatzikos C, Bryan RN; for the ACCORD MIND investigators. Effects of intensive glucose lowering on brain structure and function in people with type 2 diabetes (ACCORD MIND): a randomised open-label substudy. *Lancet Neurol* 2011;10:969-77. PMID: 21958949 PMCID: PMC3333485.
63. Linz PE, Lovato LC, Byington RP, O'Connor PJ, Leiter LA, Weiss D, Force RW, Crouse JR, Ismail-Beigi F, Simmons DL, Papademetriou V, Ginsberg HN, Elam MB. Paradoxical Reduction in HDL-C With Fenofibrate and Thiazolidinedione Therapy in Type 2 Diabetes: The ACCORD Lipid Trial. *Diabetes Care* 2014;37:686-93. PMID: 24296848 PMCID: PMC3931389.
64. Margolis KL, O'Connor PJ, Morgan TM, Buse JB, Cohen RM, Cushman WC, Cutler JA, Evans GW, Gerstein HC, Grimm RH, Lipkin EW, Narayan KMV, Riddle MC, Sood A, Goff DC. Outcomes of Combined Cardiovascular Risk Factor Management Strategies in Type 2 Diabetes: The ACCORD Randomized Trial. *Diabetes Care* 2014;37:1721-8. PMID: 24595629 PMCID: PMC4030092.
65. Margolis KL, Palermo L, Vittinghoff E, Evans GW, Atkinson HH, Hamilton BP, Josse RG, O'Connor PJ, Simmons DL, Tiktin M, Schwartz AV. Intensive Blood Pressure Control, Falls, and Fractures in Patients With Type 2 Diabetes: The ACCORD Trial. *J Gen Intern Medicine*. 2014;29:1599-606. PMID: 25127725 PMCID: PMC4242873.
66. McDuffie R, Summerson J, Reilly P, Blackwell C, Goff D, Kimel AR, Crago L, Fonseca V. The Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial and Hurricane Katrina: Lessons for managing clinical trials during and after a natural disaster. *Contemp Clin Trials* 2008;29:756-61. PMID: 18577469 PMCID: PMC2607140.
67. Miller ME, Bonds DE, Gerstein HC, for the ACCORD Investigators. The effects of baseline characteristics, glycaemia treatment approach, and glycated haemoglobin concentration on the risk of severe hypoglycaemia: post hoc epidemiological analysis of the ACCORD study. *BMJ* 2010;340:b5444. PMID: 20061360 PMCID: PMC2803743.

68. Miller ME, Williamson JD, Gerstein HC, Byington RP, Cushman WC, Ginsberg HN, Ambrosius WT, Lovato L, Applegate WB; for the ACCORD Investigators. Effects of Randomization to Intensive Glucose Control on Adverse Events, Cardiovascular Disease and Mortality in Older Versus Younger Adults in the ACCORD Trial. *Diabetes Care* 2014;37:634-43. PMID: 24170759 PMCID: PMC3931381.
69. Mottl AK, Pajewski N, Fonseca V, Ismail-Beigi F, Chew E, Ambrosius Wt, Greven C, Schubart U, Buse J. The Degree of Retinopathy is Equally Predictive for Renal and Macrovascular Outcomes in the ACCORD Trial. *J Diabetes Complications* 2014; 28:874-9. PMID: 25123755 PMCID: PMC4252726.
70. Mount DL, Feeney P, Fabricatore AN, Coday M, Bahnson J, Byington R, Phelan S, Wilmoth S, Knowler WC, Hramiak I, Osei k, Sweeney ME, Espeland MA. Constructing common cohorts from trials with overlapping eligibility criteria: implications for comparing effect sizes between trials. *Clin Trials* 2009;6:416-29. PMID: 19737845 PMCID: PMC3254056.
71. Murray AM, Barzilay JI, Lovato JF, Williamson JD, Miller ME, Marcovina S, Launer LJ; Action to Control Cardiovascular Risk in Diabetes Memory in Diabetes (ACCORD-MIND) Substudy Investigators. Biomarkers of renal function and cognitive impairment in patients with diabetes. *Diabetes Care* 2011;34:1827-32. PMID: 21715519 PMCID: PMC3142061.
72. Murray AM, Hsu FC, Williamson JD, Bryan RN, Gerstein HC, Sullivan MD, Miller ME, Leng I, Lovato LL, Launer LJ; Action to Control Cardiovascular Risk in Diabetes Follow-On Memory in Diabetes (ACCORDION MIND) Investigators. ACORDION MIND: Results of the observational extension of the ACCORD MIND randomized trial. *Diabetologia* 2017;60:69-80. PMID: 27766347.
73. Mychaleckyj JC, Craven T, Nayak U, Buse J, Crouse JR, Elam M, Kirchner K, Lorber D, Marcovina S, Sivitz W, Sperl-Hillen J, Bonds DE, Ginsberg HN. Reversibility of fenofibrate therapy-induced renal function impairment in ACCORD type 2 diabetic participants. *Diabetes Care* 2012;35:1008-14. PMID: 22432114 PMCID: PMC3329840.
74. Mychaleckyj JC, Farber EA, Chmielewski J, Artale J, Light LS, Bowden DW, Hou X, Marcovina SM. Buffy coat specimens remain viable as a DNA source for highly multiplexed genome-wide genetic tests after long term storage. *J Transl Med* 2011;9:91. PMID: 21663644 PMCID: PMC3128059.
75. Nadkarni GN, Rao V, Ismail-Beigi F, Fonseca VA, Shah SV, Simonson MS, Cantley L, Devarajan P, Parikh CR, Coca. Association of Urinary Biomarkers of Inflammation, Injury, and Fibrosis with Renal Function Decline: The ACCORD Trial. *Clin J Am Soc Nephrol* 2016;8:1342-52. PMID: 27189318 PMCID:PMC4974890.
76. O'Connor PJ, Narayan KM, Anderson R, Feeney P, Fine L, Ali MK, Simmons DL, Hire DG, Sperl-Hillen JM, Katz LA, Margolis KL, Sullivan MD. Effect of Intensive Versus Standard Blood Pressure Control on Depression and Health-Related Quality of Life in Type 2 Diabetes: The ACCORD trial. *Diabetes Care* 2012;35:1479-81. PMID: 22584134 PMCID: PMC3379590.
77. Papademetriou V, Lovato L, Doumas M, Nysten E, Mottl A, Cohen RM, Applegate B, Puntakee Z, Yale JF, Cushman WC. Chronic Kidney Disease and Intensive Glycemic Control on Cardiovascular Outcomes in Patients with Type 2 Diabetes. *Kidney International* 2015;87:649-59. PMID: 25229335.
78. Papademetriou V, Lovato L, Tsioufis C, Cushman W, Applegate WB, Mottl A, Punthakee Z, Nysten E, Doumas M; ACCORD Study Group. Effects of High Density Lipoprotein Raising Therapies on Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus, with or without Renal Impairment: The Action to Control Cardiovascular Risk in Diabetes Study. *Am J Nephrol* 2017;45:136-145 PMID: 27992863.

79. Pop-Busui R, Evans GW, Gerstein HC, Fonseca V, Fleg JL, Hoogwerf BJ, Genuth S, Grimm RH, Corson MA, Prineas R; the ACCORD Study Group. Effects of Cardiac Autonomic Dysfunction on Mortality Risk in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial. *Diabetes Care* 2010;33:1578-84. PMID: 20215456 PMCID: PMC2890362.
80. Preiss D, Tikkanen MJ, Welsh P, Ford I, Lovato L, Ealm MB, LaRosa JC, DeMicco DA, Colhoun HM, Goldenberg I, Murphy MJ, MacDonald TM, Keech AC, Ridker PM, Kjekshus J, Sattar N, McMurray JJ. Lipid-modifying therapies and risk of pancreatitis: a meta-analysis. *JAMA* 2012;308:804-11. PMID: 22910758.
81. Punthakee Z, Miller ME, Launer LJ, Williamson JD, Lazar RM, Cukierman-Yaffee T, Seaquist ER, Ismail-Beigi F, Sullivan MD, Lovato LC, Bergenstal RM, Gerstein HC; ACCORD Group of Investigators; ACCORD-MIND Investigators. Poor cognitive function and risk of severe hypoglycemia in type 2 diabetes: post hoc epidemiologic analysis of the ACCORD trial. *Diabetes Care* 2012;35:787-93. PMID: 22374637 PMCID: PMC3308284.
82. Punthakee Z, Miller ME, Simmons DL, Riddle MC, Ismail-Beigi F, Brillon DJ, Bergenstal DM, Savage PJ, Hramiak I, Largay JF, Sood A, Gerstein HC, for the ACCORD Group of Investigators. Durable Change in Glycaemic Control Following Intensive Type 2 Diabetes Management in the ACCORD Clinical Trial. *Diabetologia* 2014;57:2030-7. PMID: 24985147 PMCID: PMC4698982.
83. Raisch DW, Feeney P, Goff DC Jr, Narayan KV, O'Connor PJ, Zhang P, Hire DG, Sullivan MD. Baseline comparison of three health utility measures and the feeling thermometer among participants in the action to control cardiovascular risk in diabetes trial. *Cardiovasc Diabetol* 2012;11:35. PMID:22515638 PMCID: PMC3395556.
84. Reyes-Soffer G, Rondon-Clavo C, Ginsberg HN. Combination therapy with statin and fibrate in patients with dyslipidemia associated with insulin resistance, metabolic syndrome and type 2 diabetes mellitus. *Expert Opin Pharmacother* 2011;12:1429-38. PMID: 21426238.
85. Reyes-Soffer G, Ngai CI, Lovato L, Karmally W, Ramakrishnan R, Holleran S, Ginsberg HN. Effect of Combination Therapy with Fenofibrate and Simvastatin on Postprandial Lipemia in the ACCORD Lipid Trial. *Diabetes Care* 2013;36:422-8. PMID: 23033246 PMCID: PMC3554395.
86. Riddle MC, Ambrosius WT, Brillon DJ, Buse JB, Byington RP, Cohen RM, Goff DC Jr, Malozowski S, Margolis KL, Probstfield JL, Schnall A, Seaquist ER; Action to Control Cardiovascular Risk in Diabetes Investigators. Epidemiologic relationships between A1C and all-cause mortality during a median 3.4-year follow-up of glycemic treatment in the ACCORD trial. *Diabetes Care* 2010;33:983-90. PMID: 20427682 PMCID: PMC2858202.
87. Ronsein GE, Reyes-Soffer G, He Y, Oda m, Ginsberg H, Heinecke JW. Targeted Proteomics Identifies Paraoxonase/Arylesterase 1 (PON1) and Apolipoprotein Cs as Potential Risk Factors for Hypoalphalipoproteinemia in Diabetic Subjects Treated with Fenofibrate and Rosiglitazone. *Mol Cell Proteomics* 2016;15:1083-93. PMID 26667175 PMCID: PMC4813690.
88. Samaropoulos XF, Light L, Ambrosius WT, Marcovina SM, Probstfield J, Goff Jr DC. The Effect of Intensive Risk Factor Management in Type 2 Diabetes on Inflammatory Biomarkers. *Diabetes Res Clin Pract* 2012;95:389-98. PMID: 22019270.
89. Schwartz AV, Chen H, Ambrosius WT, Sood A, Josse RG, Bonds DE, Schnall AM, Vittinghoff E, Baucer DC, Banerji MA, Cohen RM, Hamilton BP, Isakova T, Sellmeyer DE, Simmons DL, Shibli-Rahhal A, Williamson JD, Margolis KL. Effects of TZD Use and Discontinuation On Fracture Rates in ACCORD Bone. *J Clin Endocrinol Metab* 2015;11:4059-66. PMID: 26305617 PMCID: PMC4702444.

90. Schwartz AV, Vittinghoff E, Margolis KL, Scibora LM, Palermo L, Ambrosius WT, Hue TF, Petit MA, Ensrud KE. Intensive Glycemic Control and TZD Use: Effects on Cortical and Trabecular Bone at the Radius and Tibia. *Calcified Tissue International* 2013;92:477-86. PMID: 23377193.
91. Schwartz AV, Margolis KL, Sellmeyer DE, Vittinghoff E, Ambrosius WT, Bonds DE, Josse RG, Schnell AM, Simmons DL, Hue TF, Palermo L, Hamilton BP, Green JB, Atkinson HH, O'Connor PJ, Force RW, Bauer DC. Intensive Glycemic Control Is Not Associated With Fractures or Falls in the ACCORD Randomized Trial. *Diabetes Care* 2012;35:1525-31. PMID: 22723583 PMCID: PMC3379596.
92. Seaquist ER, Miller ME, Bonds DE, Feinglos M, Goff DC Jr, Peterson K, Senior P; For the ACCORD Investigators. The Impact of Frequent and Unrecognized Hypoglycemia on Mortality in the ACCORD Study. *Diabetes Care* 2012;35:409-14. PMID: 22179956 PMCID: PMC3263892.
93. Seaquist ER, Miller ME, Fonseca V, Ismail-Beigi F, Launer LJ, Punthakee Z, Sood A. Effect of Thiazolidinediones and Insulin on Cognitive Outcomes in ACCORD-MIND. *J Diabetes Complications* 2013;27:485-91. PMID: 23680059 PMCID: PMC3748242.
94. Shah HS, Gao H, Morieri ML, Skupien J, Marvel S, Pare G, Mannino GC, Buranasupkajorn P, Mendonca C, Marcovina SM, Sigal RJ, Gerstein HC, Wagner MJ, Motsinger-Reif AA, Buse JB, Kraft P, Mychaleckyj JC, Doria A. Genetic Predictors of Cardiovascular Mortality During Intensive Glycemic Control in Type 2 Diabetes: Findings From the ACCORD Clinical Trial. *Diabetes Care* 2016;39:1915-24. PMID: 27527847 PMCID: PMC5079609.
95. Simons-Morton, DG. The Glycemia-Cardiovascular Disease Hypothesis. *Clinical and Translational Sciences* 2008;1:185-186. PMID: 20443845.
96. Simons-Morton DG, Chan JC, Kimel AR, Linz PE, Stowe CL, Summerson J, Ambrosius WT. Characteristics associated with informed consent for genetic studies in the ACCORD Trial. *Contemporary Clinical Trials* 2014;37:155-164. PMID: 24355197 PMCID: PMC3918951.
97. Siraj ES, Rubin DJ, Riddle MC, Miller ME, Hsu F, Ismail-Beigi F, Chen S, Ambrosius WT, Thomas A, Bestermann W, Buse JB, Genuth S, Joyce C, Kovacs CS, O'Connor PJ, Sigal RJ, Soloman S; ACCORD Investigators. Insulin Dose and Cardiovascular Mortality in the ACCORD Trial. *Diabetes Care*. 2015;38:2000-8. PMID: 26464212 PMCID:PMC4876773.
98. Soliman EZ, Byington RP, Bigger JT, Evans G, Okin PM, Goff DC Jr, Chen H. Effect of Intensive Blood Pressure Lowering on Left Ventricular Hypertrophy in Patients with Diabetes Mellitus: Action to Control Cardiovascular Risk in Diabetes Blood Pressure Trial. *Hypertension* 2015; 66:1123-9. PMID: 26459421 PMCID: PMC4644090.
99. Stiles MC, Seaquist ER, Yale JF, Green JB, Katz LA, Kempainen S, Light LS, Pepper PV, Zhang ZM, Soliman EZ. Is silent myocardial infarction more common in women with type 2 diabetes than in men? *J Diabetes Complications* 2012;26:118-22. PMID: 22446034 PMCID: PMC3348405.
100. Sullivan M, Evans G, Anderson R, O'Connor P, Raisch D, Simmons DL, Narayan V. Diabetes Symptoms and Distress in ACCORD Trial Participants: Relationship to Baseline clinical Variables. *Clinical Diabetes* 2012;30:101-8. PMID: 22141437.
101. Sullivan MD, Anderson RT, Aron D, Atkinson HH, Bastien A, Chen GJ, Feeney P, Gafni A, Hwang W, Katz LA, Narayan KMV, Nwachuku C, O'Connor PJ, Zhang P, for the ACCORD Study Group. Health-Related Quality of Life and Cost-Effectiveness Components of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial: Rationale and Design. *Am J Cardiol* 2007;99(suppl):90i-102i. PMID: 17599429.
102. Sullivan MD, O'Connor P, Feeney P, Hire D, Simmons DL, Raisch DW, Fine LJ, Narayan KM, Ali MK, Katon WJ. Depression Predicts All-Cause Mortality: Epidemiological evaluation from the ACCORD HRQL substudy. *Diabetes Care* 2012;35:1708-15 PMID: 22619083 PMCID:PMC3402260.

103. Sullivan MD, Katon WJ, Lovato LC, Miller ME, Murray AM, Horowitz KR, Bryan RN, Gerstein HC, Marcovina S, Akpunonu BE, Johnson J, Yale JF, Williamson J, Launer LJ. Association of depression with accelerated cognitive decline among patients with Type 2 diabetes in the ACCORD-MIND Trial. *JAMA Psychiatry* 2013; 70:1041-7. PMID: 23945905 PMCID: PMC4212406.
104. Thethi T, Rajapurkar M, Walker P, McDuffie R, Goff DC Jr, Probstfield J, Yau CL, Shah S, Christians U, Buse J, Fonseca V. Urinary catalytic iron in patients with type 2 diabetes without microalbuminuria--a substudy of the ACCORD Trial. *Clin Chem* 2011;57:341-4. PMID: 21159897.
105. Williamson JD, Miller ME, Bryan RN, Lazar RM, Coker LH, Johnson J, Cukierman T, Horowitz KR, Murray A, Launer LJ, for the ACCORD Study Group. The Action to Control Cardiovascular Risk in Diabetes Memory in Diabetes Study (ACCORD-MIND): Rationale, Design, and Methods. *Am J Cardiol* 2007;99(suppl):112i-122i. PMID: 17599421.
106. Williamson, J, Launer L, Bryan N, Coker L, Lazar R, Gerstein H, Murray A, Sullivan M, Horowitz K, Ding J, Marcovina S, Lovato L, Lovato, J, Margolis K, Davatzikos C, Barzilay J, Ginsberg H, Linz P, Miller M. Cognitive Function and Brain Structure in Persons with Type 2 Diabetes After Intensive Lowering of Blood Pressure and Lipid Levels: A Randomized Clinical Trial. *JAMA Int Med* 2014;174:324-33. PMID: 24493100 PMCID: PMC4423790.
107. Zhang Z, Lovato J, Battapady H, Davatzikos C, Gerstein HC, Ismail-Beigi F, Launer LJ, Murray A, Punthakee Z, Tirado AA, Williamson J, Miller ME. Effect of Hypoglycemia on Brian Structure in People with Type 2 Diabetes: Epidemiological Analysis of the ACCORD-MIND MRI Trial. *Diabetes Care* 2014;37:3279-85. PMID: 25267796 PMCID: PMC4237972.